JP2005060406A5 - - Google Patents

Download PDF

Info

Publication number
JP2005060406A5
JP2005060406A5 JP2004293637A JP2004293637A JP2005060406A5 JP 2005060406 A5 JP2005060406 A5 JP 2005060406A5 JP 2004293637 A JP2004293637 A JP 2004293637A JP 2004293637 A JP2004293637 A JP 2004293637A JP 2005060406 A5 JP2005060406 A5 JP 2005060406A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004293637A
Other languages
Japanese (ja)
Other versions
JP2005060406A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2005060406A publication Critical patent/JP2005060406A/ja
Publication of JP2005060406A5 publication Critical patent/JP2005060406A5/ja
Pending legal-status Critical Current

Links

JP2004293637A 1993-04-27 2004-10-06 ワクチン用免疫原性lhrhペプチド構築体および合成普遍免疫刺激器 Pending JP2005060406A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5716693A 1993-04-27 1993-04-27
US22927594A 1994-04-14 1994-04-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP52461494A Division JP3795914B2 (ja) 1993-04-27 1994-04-28 ワクチン用免疫原性lhrhペプチド構築体および合成普遍免疫刺激器

Publications (2)

Publication Number Publication Date
JP2005060406A JP2005060406A (ja) 2005-03-10
JP2005060406A5 true JP2005060406A5 (enExample) 2005-09-08

Family

ID=26736147

Family Applications (2)

Application Number Title Priority Date Filing Date
JP52461494A Expired - Lifetime JP3795914B2 (ja) 1993-04-27 1994-04-28 ワクチン用免疫原性lhrhペプチド構築体および合成普遍免疫刺激器
JP2004293637A Pending JP2005060406A (ja) 1993-04-27 2004-10-06 ワクチン用免疫原性lhrhペプチド構築体および合成普遍免疫刺激器

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP52461494A Expired - Lifetime JP3795914B2 (ja) 1993-04-27 1994-04-28 ワクチン用免疫原性lhrhペプチド構築体および合成普遍免疫刺激器

Country Status (11)

Country Link
EP (1) EP0708656B1 (enExample)
JP (2) JP3795914B2 (enExample)
AT (1) ATE221387T1 (enExample)
AU (1) AU687805B2 (enExample)
CA (1) CA2161445C (enExample)
DE (1) DE69431114T2 (enExample)
DK (1) DK0708656T3 (enExample)
ES (1) ES2180576T3 (enExample)
FI (1) FI955101A7 (enExample)
NO (1) NO316121B1 (enExample)
WO (1) WO1994025060A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607727B1 (en) 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
US6235288B1 (en) 1992-08-26 2001-05-22 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
DE69434954T2 (de) * 1993-02-26 2007-12-20 The Scripps Research Institute, La Jolla Peptide zum Induzieren einer Antwort der zytotoxischen T-Lymphozyten gerichtet gegen das Hepatitis-B-Virus
US5688506A (en) * 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
WO1995026365A1 (en) * 1994-03-28 1995-10-05 United Biomedical, Inc. Synthetic peptide based immunogens for the treatment of allergy
US6410022B1 (en) * 1995-05-01 2002-06-25 Avant Immunotherapeutics, Inc. Modulation of cholesteryl ester transfer protein (CETP) activity
ATE234109T1 (de) 1995-06-06 2003-03-15 Avant Immunotherapeutics Inc Cetp zur erhöhung des hdl-cholesterol-gehalts
US5843462A (en) 1995-11-30 1998-12-01 Regents Of The University Of Minnesota Diphtheria toxin epitopes
HUP9901109A3 (en) 1996-03-01 1999-11-29 Novartis Ag Peptide immunogens for vaccination against and treatment of allergy
US6261561B1 (en) * 1996-04-19 2001-07-17 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of stimulating an immune response by administration of host organisms that express intimin alone or as a fusion protein with one or more other antigens
WO1997040161A1 (en) * 1996-04-19 1997-10-30 Henry M. Jackson Foundation For The Advancement Of Military Medecine Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability
US6846808B1 (en) 1996-05-01 2005-01-25 Avant Immunotherapeutics, Inc. Plasmid-based vaccine for treating atherosclerosis
US6284533B1 (en) 1996-05-01 2001-09-04 Avant Immunotherapeutics, Inc. Plasmid-based vaccine for treating atherosclerosis
US6309646B1 (en) 1996-05-09 2001-10-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Protein-polysaccharide conjugate vaccines and other immunological reagents prepared using homobifunctional and heterobifunctional vinylsulfones, and processes for preparing the conjugates
JP4651753B2 (ja) * 1996-06-25 2011-03-16 ペプスキャン システムズ ベー.フェー. 不安定結合による担体結合抗原から成るワクチン
WO1999007839A2 (en) * 1997-08-05 1999-02-18 Vlaams Interuniversitair Instituut Voor Biotechnologie Immunoprotective influenza antigen and its use in vaccination
EP1037663A2 (en) 1997-12-16 2000-09-27 Regents Of The University Of Minnesota Methods to treat undesirable immune responses
US6090388A (en) * 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders
US6107021A (en) * 1998-06-20 2000-08-22 United Biomedical, Inc. Synthetic peptide vaccines for foot-and-mouth disease
US6025468A (en) * 1998-06-20 2000-02-15 United Biomedical, Inc. Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
TWI227241B (en) 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
WO2000032626A1 (en) * 1998-11-25 2000-06-08 Regents Of The University Of Minnesota Methods of using epitope peptides of human pathogens
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
EP1303533A2 (en) * 2000-05-05 2003-04-23 Aphton Corporation Chimeric peptide immunogens, their preparation and use
US6780969B2 (en) * 2000-12-22 2004-08-24 United Biomedical, Inc. Synthetic peptide composition as immunogens for prevention of urinary tract infection
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
US8088388B2 (en) * 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
ES2368907T3 (es) * 2002-04-19 2011-11-23 The Governing Council Of The University Of Toronto Procedimientos y composiciones inmunológicas para el tratamiento de la enfermedad de alzheimer.
NZ564694A (en) 2003-04-22 2009-11-27 Sod Conseils Rech Applic Peptide vectors
CA2579775A1 (en) * 2004-09-10 2006-03-16 The Council Of The Queensland Institute Of Medical Research (Qimr) Truncated lhrh formulations
WO2006125076A2 (en) 2005-05-18 2006-11-23 Trinity Biosystems, Inc. Methods and compositions for immunizing against chlamydia infection
CN101189026A (zh) * 2005-06-01 2008-05-28 辉瑞产品公司 用于治疗尿失禁的疫苗组合物及方法
JP2010539058A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療剤としてのtrap−14
JP4535174B2 (ja) 2008-07-11 2010-09-01 トヨタ自動車株式会社 車両の制御装置および制御方法
CN104244973B (zh) 2012-11-16 2017-10-20 美国联合生物医学公司 针对口蹄疫(fmd)的基于合成肽的紧急疫苗
EP3191119A4 (en) * 2014-07-25 2018-01-24 United Biomedical, Inc. Immunogenic lhrh composition and use thereof in pigs
CN110945025B (zh) * 2017-03-30 2023-11-03 Ecs前胃泌素股份有限公司 用于检测前列腺癌的组合物和方法
AU2019404226A1 (en) * 2018-12-19 2021-07-15 United Biomedical, Inc. Artificial promiscuous T helper cell epitopes as immune stimulators for synthetic peptide immunogens
TW202144387A (zh) * 2020-02-11 2021-12-01 美商聯合生物醫學公司 針對胰島澱粉樣多肽(iapp)的胜肽免疫原及其預防和治療與聚集iapp相關疾病的製劑

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4613586A (en) * 1984-04-19 1986-09-23 Board Of Trustees Of The Leland Stanford Junior University Gastrin releasing peptide-like peptides
US4608251A (en) * 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
EP0301850A3 (en) * 1987-07-31 1990-10-31 Syntex (U.S.A.) Inc. Lhrh antagonist analogs and 19-nor-progestational steroids for therapy
GB8812214D0 (en) * 1988-05-24 1988-06-29 Hoffmann La Roche Use of peptide from circumsporozoite protein of p falciparum as universally recognized t-cell epitope
US5171835A (en) * 1988-10-21 1992-12-15 The Administrators Of The Tulane Educational Fund LHRH antagonists
GB8913737D0 (en) * 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment
GB8924438D0 (en) * 1989-10-31 1989-12-20 Hoffmann La Roche Vaccine composition
IT1237764B (it) * 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
US5500366A (en) * 1990-09-18 1996-03-19 Biotech Australia Pty. Ltd. Polynucleotide encoding T-cell epitopes of the protein TraT
WO1992020370A1 (en) * 1991-05-13 1992-11-26 Regents Of The University Of California Liposomal polysaccharide vaccines
CA2115839C (en) * 1991-08-26 2010-06-01 Maria A. Vitiello Hla-restricted hepatitis b virus ctl epitopes

Similar Documents

Publication Publication Date Title
BE2024C508I2 (enExample)
BE2023C542I2 (enExample)
BE2022C549I2 (enExample)
BE2021C001I2 (enExample)
BE2020C513I2 (enExample)
BE2020C517I2 (enExample)
BE2019C540I2 (enExample)
BE2019C523I2 (enExample)
BE2019C548I2 (enExample)
BE2019C506I2 (enExample)
BE2018C045I2 (enExample)
BE2020C525I2 (enExample)
BE2017C063I2 (enExample)
BE2017C027I2 (enExample)
BE2017C023I2 (enExample)
BE2017C002I2 (enExample)
BE2016C067I2 (enExample)
BE2016C014I2 (enExample)
BE2015C041I2 (enExample)
BE2015C038I2 (enExample)
BE2015C014I2 (enExample)
BE2015C015I2 (enExample)
BE2015C066I2 (enExample)
DE602005006830D1 (enExample)
JP2005060406A5 (enExample)